Skip to main content
ANTEROGEN CO., LTD. logo

ANTEROGEN CO., LTD. — Investor Relations & Filings

Ticker · 065660 ISIN · KR7065660003 KO Manufacturing
Open in API
Filings indexed 267 across all filing types
Latest filing 2019-03-12 Proxy Solicitation & In…
Country KR South Korea
Listing KO 065660

About ANTEROGEN CO., LTD.

http://anterogen.com

ANTEROGEN CO., LTD. is a bio-venture company engaged in the research, development, and commercialization of cell therapy products and orphan drugs. The company specializes in utilizing adult stem cells, particularly adipose-derived mesenchymal stem cells, to create innovative treatments. Its key commercialized products include Cupistem®, an autologous stem cell therapy for Crohn's fistula, and Queencell®. Anterogen's research pipeline extends to applications for musculoskeletal diseases, spinal injuries, and cardiovascular conditions. The company also offers stem cell banking services.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Solicitation of Proxy' (위임장 권유) filed by Antrogen Co., Ltd. with the Financial Services Commission (금융위원회) in South Korea. It includes details about the upcoming Annual General Meeting (AGM), the purpose of the solicitation, and the financial statements (balance sheet, income statement, etc.) for the fiscal year 2018. This type of document is specifically designed to provide shareholders with information and request their votes for the meeting, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2019-03-12 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Anterogen, which includes detailed agenda items, voting procedures, and financial statements (Balance Sheet, Income Statement, etc.) for the 19th fiscal year. This type of document is a standard proxy statement/information circular provided to shareholders to prepare them for the Annual General Meeting. In the context of the provided categories, this fits the 'Proxy Solicitation & Information Statement' (PSI) classification, as it contains the necessary information for shareholders to exercise their voting rights.
2019-03-07 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a third-party paid-in capital increase). It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2019-02-26 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (AlltoGen) announcing a significant change (over 30%) in revenue and profit structure. It provides key financial highlights, including revenue, operating profit, and net income, and explicitly states these are preliminary figures pending final audit. This type of disclosure is a standard regulatory requirement for listed companies in Korea to report material financial changes, fitting the 'Earnings Release' (ER) category as it provides the initial announcement of financial performance highlights.
2019-02-19 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Antrogen. It outlines the date, location, and agenda items (such as approval of financial statements, election of directors, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming votes, which falls under the Proxy Solicitation & Information Statement category.
2019-02-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Lee Sung-gu) of Anterogen. This type of filing, which details personal share transactions (in this case, '장내매도' or on-market sales) by company insiders, is classified as a Director's Dealing report.
2019-02-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.